- Poster presentation
- Open Access
Do precursor polyp burdens help distinguish Lynch versus non-Lynch microsatellite unstable colorectal cancers?
© Kalady et al; licensee BioMed Central Ltd. 2010
- Published: 25 May 2010
- Lynch Syndrome
- Serrate Polyp
- Malignant Polyp
- Lynch Syndrome Patient
- Methylator Pathway
Microsatellite instability (MSI) within colorectal cancers (CRC) may develop through inherited germline mutations in mismatch repair (MMR) genes (Lynch Syndrome) or sporadic epigenetic methylation of tumor suppressor or repair genes (methylator pathway). Although the molecular mechanisms in each pathway have been described, their associated precursor polyp burdens are not well-defined. This study analyzes precursor polyp burdens occurring within patients with MSI-H colorectal cancers associated with Lynch Syndrome (LS) or those with a methylator pathway cancer phenotype.
MSI-H CRCs were identified either from an inherited CRC registry or clinic-based frozen tissue bank. Patients with confirmed MMR germline defects were defined as LS. MSI-H tumors considered to be methylators were defined by previously determined CpG island methylator phenotype (CIMP). These two groups were also compared to MSS/CIMP-negative tumor controls. Corresponding patient demographics, all prior preoperative colonoscopy, operative, and pathology reports for polyp characteristics were reviewed.
114 patients were included: 29 LS, 22 Methylator, and 63 MSS/CIMP-negative. No differences were observed between groups in terms of gender, total number or percentage of patients with polyps, and polyp location. The LS group was younger, had larger polyps size (1.0 em vs. methylators, 0.4 cm, p=0.02), and more malignant polyps (4/30) vs. methylators (0/26) and MSS/CIMP-N (1/1 00), p=0.01. Although adenomas were the most prevalent polyp type in all groups, serrated polyps were located more frequently in the right colon in methylators (9 of 12) compared to LS patients (1 of 5), p=0.01. Importantly, the percentage of serrated polyps varied by group with 46% (12/26) incidence in methylators compared to 17% (5/30) in LS (p=0.02) and 24% (24/100) in MSS/CIMP-negative patients (p=0.03).
Polyp burdens associated with MSI-H CRC vary depending on the etiology of microsatellite instability. While LS patients tend to develop adenomas similar to the general population, an increased relative burden of serrated polyps is associated with the methylator phenotype. These findings may help guide investigation into suspected Lynch syndrome.
This article is published under license to BioMed Central Ltd.